Composition specification of teicoplanin based on its estimated relative bioavailability
Antonio Boix-Montañes1, Alfredo Garcia-Arieta
1Departamento de Farmacia y Tecnologia Farmacéutica, Facultad de Farmacia, Universidad de Barcelona , Barcelona , Spain and.
Drug Development and Industrial Pharmacy
|February 11, 2014
Summary
Pharmacopeial specifications for teicoplanin may need adjustment to ensure consistent pharmacokinetic profiles across batches. Current specifications allow for significant variability in active components, impacting drug exposure.
Area of Science:
- Pharmacology
- Pharmaceutical Sciences
- Drug Composition Analysis
Background:
- Teicoplanin, a fermentative antibiotic, comprises multiple active components with similar antibacterial effects but varying pharmacokinetic properties.
- Batch-to-batch variations in teicoplanin subcomponent proportions can lead to differences in systemic exposure, even within existing pharmacopeial limits.
Purpose of the Study:
- To evaluate modifications to current pharmacopeial specifications for teicoplanin composition.
- To ensure pharmacokinetic equivalence among all batches that comply with pharmacopeial standards.
Main Methods:
- Predicted the Area Under the Curve (AUC) for plasma levels of teicoplanin across various experimental and theoretical extreme batches.
- Calculated AUC based on individual teicoplanin active subcomponents.
- Assessed the equivalence between generic and reference teicoplanin products using AUC ratios.
Main Results:
- Batches meeting current pharmacopeial specifications exhibited predicted AUC differences exceeding 40%.
- This variability surpasses the typical ±5% range for chemically synthesized drugs.
- No significant AUC differences were observed for the reference product when compared to pooled data.
Conclusions:
- Alternative specifications for active component composition can be established.
- These revised specifications aim to maintain a ±10% interval between all pharmacopeia-compliant teicoplanin batches.
More Related Videos
11:28A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically
Published on: September 9, 2015
33.2K
11:17Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
11.6K
Related Concept Videos
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
230
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
230
01:13Bioavailability: Overview
4.4K
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
4.4K
01:17Bioavailability: Overview
828
Bioavailability refers to the proportion of an administered drug that reaches the systemic circulation in its active, unaltered form. It is a crucial pharmacokinetic parameter that determines the effectiveness of a drug in achieving its intended therapeutic outcomes. The route of administration significantly influences bioavailability, with intravenous administration achieving 100% bioavailability as the drug directly enters the bloodstream. In contrast, oral administration often results in...
828
01:27Bioavailability Study Design: Absolute Versus Relative Bioavailability
648
Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
648
01:16Bioequivalence: Overview
2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K
01:30Modified-Release Drug Delivery Systems: Bioavailability
170
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
170